MedPath

湖南洞庭药业股份有限公司

Ownership
-
Established
1997-03-26
Employees
-
Market Cap
-
Website
hndtyy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

126

NMPA:126

Drug Approvals

Olanzapine Tablets

Product Name
奥氮平片
Approval Number
国药准字H20253703
Approval Date
Mar 25, 2025
NMPA

Olanzapine Tablets

Product Name
奥氮平片
Approval Number
国药准字H20253702
Approval Date
Mar 25, 2025
NMPA

Risperidone Tablets

Product Name
利培酮片
Approval Number
国药准字H20253707
Approval Date
Mar 25, 2025
NMPA

Risperidone Tablets

Product Name
利培酮片
Approval Number
国药准字H20253706
Approval Date
Mar 25, 2025
NMPA

Agomelatine Tablets

Product Name
阿戈美拉汀片
Approval Number
国药准字H20253553
Approval Date
Mar 4, 2025
NMPA

Oxazepam Tablets

Product Name
奥沙西泮片
Approval Number
国药准字H20253141
Approval Date
Jan 14, 2025
NMPA

Aripiprazole Tablets

Product Name
阿立哌唑片
Approval Number
国药准字H20249302
Approval Date
Nov 5, 2024
NMPA

Escitalopram Oxalate

Product Name
草酸艾司西酞普兰
Approval Number
国药准字H20140130
Approval Date
Oct 18, 2024
NMPA

Escitalopram Oxalate Tablets

Product Name
草酸艾司西酞普兰片
Approval Number
国药准字H20143391
Approval Date
Oct 14, 2024
NMPA

Fluvoxamine Maleate Tablets

Product Name
马来酸氟伏沙明片
Approval Number
国药准字H20244967
Approval Date
Sep 26, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 13
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.